Neuraxis (NRXS) Total Current Liabilities (2022 - 2025)
Neuraxis (NRXS) posted Total Current Liabilities of $2.8 million for Q4 2025, down 11.28% sequentially from $3.1 million in Q3 2025, and up 14.74% YoY from $2.4 million in Q4 2024.
Neuraxis (NRXS) Total Current Liabilities (2022 - 2025) Analysis & Trends
Neuraxis has reported Total Current Liabilities for 4 years, with the latest figure at $2.8 million in Q4 2025.
- Quarterly Total Current Liabilities rose 14.74% year-over-year to $2.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.8 million (up 14.74% YoY) and the FY2025 annual result came in at $2.8 million, up 14.74% from the prior year.
- Total Current Liabilities retreated to $2.8 million in Q4 2025 per NRXS's latest filing, from $3.1 million in the prior quarter.
- Over five years, Total Current Liabilities peaked at $11.4 million in Q2 2023 and troughed at $1.9 million in Q4 2023.
- A 4-year average of $4.1 million and a median of $2.7 million in 2024 frame the typical range for Total Current Liabilities.
- The sharpest annual moves came in 2023 and 2024: Total Current Liabilities plunged 72.98% in 2023, then increased 29.04% in 2024.
- Over 4 years, Total Current Liabilities stood at $7.0 million in 2022, then slumped by 72.98% to $1.9 million in 2023, then grew by 29.04% to $2.4 million in 2024, then climbed by 14.74% to $2.8 million in 2025.
- According to Business Quant data, Total Current Liabilities over the past three periods registered $2.8 million, $3.1 million, and $2.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.51 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 2.49 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 438.74 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 630.93 Mn |
| 10 | Neuraxis | 74.54 Mn | 66.21 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.79 Mn |
| Sep 30, 2025 | 3.15 Mn |
| Jun 30, 2025 | 2.35 Mn |
| Mar 31, 2025 | 2.10 Mn |
| Dec 31, 2024 | 2.43 Mn |
| Sep 30, 2024 | 2.66 Mn |
| Jun 30, 2024 | 7.59 Mn |
| Mar 31, 2024 | 3.82 Mn |
| Dec 31, 2023 | 1.89 Mn |
| Sep 30, 2023 | 2.26 Mn |
| Jun 30, 2023 | 11.43 Mn |
| Dec 31, 2022 | 6.98 Mn |